Farajallah Awny Samaan Botros 4

What Happened
Farajallah Awny Samaan Botros, Chief Medical Officer of Takeda Pharmaceutical Co. Ltd. (TAK), was granted 17,554 restricted stock units (RSUs) on July 1, 2026. The grant was reported as acquired at $0.00 (code A — award/grant), so there was no cash purchase. Each RSU represents a contingent right to receive one American Depositary Share; the RSUs vest in three equal annual installments beginning July 1, 2027.

Key Details

• Transaction date: July 1, 2026; Report filed: July 6, 2026.
• Grant: 17,554 RSUs; reported acquisition price $0.00 (award).
• Footnote: Each RSU converts to one American Depositary Share; vesting in three equal annual installments starting 7/1/2027.
• Shares owned after the transaction: not disclosed in the filing.
• Filing timeliness: filed July 6 for the July 1 transaction — this appears to be after the standard two-business-day deadline for Form 4s.

Context
This was an equity award, not an open-market purchase or sale. RSU grants are common executive compensation and represent future issuance of shares if and when they vest; they do not by themselves signal immediate buying or selling activity. For retail investors, awards are informative about compensation alignment but should be interpreted alongside other insider activity and company fundamentals.